Charles River Laboratories International Inc (CRL)
195.77
+1.58
(+0.81%)
USD |
NYSE |
Nov 22, 16:00
195.80
+0.03
(+0.02%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 10.01B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 0.42% |
| Valuation | |
| PE Ratio | 24.44 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.490 |
| Price to Book Value | 2.647 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.6151 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 64.10% |
Profile
| Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services. |
| URL | https://www.criver.com |
| Investor Relations URL | https://ir.criver.com |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Feb. 14, 2025 (est.) |
| Last Earnings Release | Nov. 06, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services. |
| URL | https://www.criver.com |
| Investor Relations URL | https://ir.criver.com |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Feb. 14, 2025 (est.) |
| Last Earnings Release | Nov. 06, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |